Walmart's low-cost insulin promises to revolutionize insulin access and affordability for diabetic patients in U.S.

July 02, 2021
Last Updated:
July 02, 2021
CPG More...
Consumer Health and Wellness More...
Truly disruptive

Insulin prices are more than eight times higher in the U.S. than in 32 high-income nations. Insulin's out-of-pocket (OOP) costs also continue to rise in the U.S., although net costs to pharmacy benefit managers (PBMs) are dropping. These facts underscore the grim reality for more than 10 million Americans who are insulin-dependent diabetics, where OOP costs are a major expense, even if insured. Walmart's brand of analog insulins is projected to save customers 58% to 75% compared to branded insulin products. Walmart is poised to become a major player in the U.S. diabetes market. Clients, now is the time to engage with Walmart, as it will most certainly be looking to build an integrated digital ecosystem, as Roche did in India.

For the original news article, click here .

Further Reading

Amazon's $6 for a six-month supply of prescription drugs means investors in retail pharma must be extra-cautious right now

Case Study | July 15, 2021

When Walmart started its $4 generic drug program, it had an overnight chilling effect on both pharmacy retail companies like CVS and Rite Aid and mom‑and‑pop pharmacies, which had to drastically slash their pricing to compete. This was possible largely because of the historically high margins on ... Not part of subscription

Novo Nordisk looks beyond diabetes in its most recent therapeutic program acquisition

News Commentary | July 13, 2021

Novo Nordisk has mostly focused on diabetes care. Hence, this latest acquisition for the treatment of a rare heart disease known as ATTR cardiomyopathy seems out of character. However, the company has been building a pipeline of drug assets in the rare diseases category, starting with hemophilia and... Not part of subscription

Capturing Value from Food Traceability

Presentation | February 16, 2022

Political, economic, social, and technological factors are all elevating the need for end‑to‑end food traceability and transparency, with the COVID‑19 pandemic acting as a force multiplier. The reasons for agrifood companies to implement traceability and transparency tools are many, but ... Not part of subscription